Join our daily newsletter At The Bell to receive exclusive market insights
- Archer Materials (AXE) reports a “major milestone” in the development of its biochip technology system for disease detection
- The company has implemented an early-stage prototype biochip platform that aims to integrate graphene field effect transistors (gFET) into fluidic systems to create mini lab-on-a-chip devices
- This follows a recent achievement of designing and fabricating a liquid-gated gFET, which can operate in wet environments such as in liquids
- Archer Materials will use the biochip platform to test in-house biosensing chips so it can collect data to establish commercial partnerships
- Company shares closed 4.55 per cent higher at 69 cents
Archer Materials (AXE) has reported a “major milestone” in the development of its biochip technology system for disease detection.
The company on Wednesday said it had implemented an early-stage prototype of an integrated biochip platform for biosensing.
Archer’s biochip innovation aims to integrate graphene field effect transistors (gFETs) into advanced fluidic systems to create mini lab-on-a-chip device platforms — essentially combining laboratory functions into a single chip — for medical diagnostics.
Over the last 12 months, Archer has reportedly made significant progress that supports the development of a prototype biochip technology system aimed at detecting diseases through the analysis of biological specimen droplets using graphene-based sensor devices.
Most recently, the company designed and fabricated a liquid-gated gFET, which can operate in wet environments such as in liquids.
The company said implementing the early-stage prototype was a milestone toward its commercialisation goals.
“Archer will focus on building advanced and sophisticated versions of this system, which could be used in commercial or applied research settings,” CEO Mohammad Choucair said.
Archer’s early-stage prototype biochip system platform. Source: Archer Materials
The company will use the biochip platform to test in-house biosensing chips so it can collect data to establish commercial partnerships with companies around the world.
It said it would be able to “quickly” assess the impact of design changes within the biochip and the effectiveness of detection mechanisms.
AXE expects this to lead to accelerated development of its proposed sensing pathways to detect biologically relevant information and reduce the cost of each development cycle.
Company shares closed 4.55 per cent higher at 69 cents.
